EUR/USD likely to find a peak near 1.25: UBS
On Monday, Deutsche Bank (ETR:DBKGn) analysts downgraded Intuitive Surgical stock (NASDAQ: NASDAQ:ISRG) from a Hold to a Sell rating. The analysts also adjusted the price target to $440 from the previous $515, placing it within the current analyst range of $350-$675. This change reflects the bank’s updated outlook on the company’s performance and market position. According to InvestingPro data, the stock is currently trading at elevated multiples, with a P/E ratio of 80.
The announcement comes ahead of an investor webinar hosted by Deutsche Bank, featuring Jon Reuter, COO of Keck Hospitals of USC. The webinar, scheduled for Monday at 10:00 a.m. ET, will explore how Intuitive Surgical’s hospital customers are considering the adoption of remanufactured Endowrist instruments. USC’s robotic surgery program, which operates ten da Vinci (EPA:SGEF) systems, is actively evaluating these instruments. The company has maintained strong revenue growth of 19% over the last twelve months.
Intuitive Surgical’s da Vinci platform, recognized as a significant innovation in the medical technology sector, was the first soft-tissue surgical robot approved by the FDA in 2000. Since then, the company has expanded its global presence with an installed base of over 10,000 systems worldwide. These systems support more than 3 million robotic surgeries annually, performed by over 50,000 surgeons.
The company’s pioneering technology has been influential in the field of robotic surgery, driving widespread adoption and utilization across the healthcare industry. The upcoming webinar aims to provide insights into the evolving landscape of robotic surgical instruments and their impact on healthcare institutions like USC.
In other recent news, Intuitive Surgical has reported several significant developments. The company received U.S. FDA clearance for its da Vinci Single Port (SP) system for colorectal surgery, specifically for transanal local excision/resection. This approval enhances the system’s capabilities, allowing for minimally invasive procedures through natural orifices, which could lead to improved patient outcomes and quicker recovery times. Additionally, Intuitive Surgical has announced a major leadership change, with Dave Rosa set to become CEO on July 1, 2025, succeeding Gary Guthart, who will transition to Executive Chair of the Board.
In a strategic move to enhance shareholder value, Intuitive Surgical has significantly increased its stock repurchase program, authorizing up to $4 billion in buybacks. This decision has garnered a positive outlook from Wolfpack Research, a firm known for its short-biased research, which is now taking a long position on the company. Furthermore, Erste Group analysts have upgraded Intuitive Surgical’s stock rating from Hold to Buy, citing anticipated improvements in turnover and profits by 2025. Despite current challenges due to new tariffs impacting profitability, analysts express confidence in the company’s ability to navigate these issues and achieve long-term growth.
Lastly, Intuitive Surgical’s decision to insource the production of surgical drapes has implications for UFP Technologies, a key supplier, as the company shifts to manufacturing in-house and sourcing from competitors. These recent developments highlight Intuitive Surgical’s strategic efforts to strengthen its market position and improve its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.